[Progress of treatment of new targets in gastric cancer].

In recent years, biomarkers such as HER-2, PD-L1, and Claudin 18.2 (CLDN 18.2) have provided new opportunities for precision treatment. HER-2-targeted therapies have achieved substantial advancements, while immune checkpoint inhibitors have demonstrated survival benefits in a subset of, but not all patients. CLDN18.2, as an emerging target, has been proven in multiple studies to have potential in the treatment of advanced gastric cancer, with drugs targeting CLDN18.2, such as Zolbetuximab, already approved, opening new pathways for precision treatment. Furthermore, research on targets such as FGFR2b, MET, DKK1, and TROP2 continues, aiming to offer personalized treatment plans for patients with different biomarker profiles. Although the current biomarkers have certain limitations in treatment, the continuous discovery of new targets and the deepening of clinical research hold great promise for precision treatment of gastric cancer and are expected to significantly improve the prognosis of advanced gastric cancer patients.